




Article

Neuroimmune Response Mediated by Cytokines in Natural Scrapie after Chronic Dexamethasone Treatment

Isabel M. Guijarro ¹, Moisés Garcés ¹, Pol Andrés-Benito ² , Belén Marín ¹, Alicia Otero ¹, Tomás Barrio ¹, Margarita Carmona ², Isidro Ferrer ² , Juan J. Badiola ¹ and Marta Monzón ^{1,*} 

¹ Research Centre for Encephalopathies and Transmissible Emerging Diseases, Institute for Health Research Aragón (IIS), University of Zaragoza, C/Miguel Servet 155, 50013 Zaragoza, Spain; isabelmariagt91@gmail.com (I.M.G.); moisesgarcés1@gmail.com (M.G.); belenm@unizar.es (B.M.); aliotgar@hotmail.com (A.O.); tbarrio_sc@hotmail.com (T.B.); badiola@unizar.es (J.J.B.)

² Departamento de Patología y Terapéutica Experimental, Universidad de Barcelona, 08907 Barcelona, Spain; pol.andres.benito@gmail.com (P.A.-B.); mcarmona@idibell.cat (M.C.); 8082ifa@gmail.com (I.F.)

* Correspondence: mmonzon@unizar.es; Tel.: +00-34-976-762944

Abstract: The actual role of prion protein-induced glial activation and subsequent cytokine secretion during prion diseases is still incompletely understood. The overall aim of this study is to assess the effect of an anti-inflammatory treatment with dexamethasone on different cytokines released by neuroglial cells that are potentially related to neuroinflammation in natural scrapie. This study emphasizes the complex interactions existent among several pleiotropic neuromodulator peptides and provides a global approach to clarify neuroinflammatory processes in prion diseases. Additionally, an impairment of communication between microglial and astroglial populations mediated by cytokines, mainly IL-1, is suggested. The main novelty of this study is that it is the first one assessing in situ neuroinflammatory activity in relation to chronic anti-inflammatory therapy, gaining relevance because it is based on a natural model. The cytokine profile data would suggest the activation of some neurotoxicity-associated route. Consequently, targeting such a pathway might be a new approach to modify the damaging effects of neuroinflammation.

Keywords: scrapie; cytokines; dexamethasone; neuroinflammation; prion diseases



Citation: Guijarro, I.M.; Garcés, M.; Andrés-Benito, P.; Marín, B.; Otero, A.; Barrio, T.; Carmona, M.; Ferrer, I.; Badiola, J.J.; Monzón, M.

Neuroimmune Response Mediated by Cytokines in Natural Scrapie after Chronic Dexamethasone Treatment.

Biomolecules **2021**, *11*, 204.

<https://doi.org/10.3390/biom11020204>

Received: 14 January 2021

Accepted: 27 January 2021

Published: 2 February 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Scrapie is considered the prototype of prion diseases, which are a group of neurodegenerative disorders caused by the conversion of a cellular protein into a pathological isoform called prion.

Neuroinflammation is currently a widely accepted concept in neurodegeneration, particularly in prion diseases [1–4]. The neuroinflammatory process is defined as the prolonged activation of neuroglial cells with the corresponding production of inflammatory cytokines [5]. Consequently, there is a particular interest in investigating the roles of the innate and adaptive immune systems in several neurodegenerative disorders, with neuroglia as a key element in the neuropathological process [6–8].

A relevant number of studies have proposed a crucial role for cytokines as neuroinflammatory mediators in the cellular communication in these prion diseases [3,9–14]. The detection of these cytokines was described coinciding with the onset of clinical signs in both a murine model [9] and Creutzfeldt–Jakob disease (CJD) [15]. Moreover, a recent study described the presence of several genes implicated in inflammation that are upregulated in early phases of prion infection [16]. Nevertheless, although an altered profile of inflammatory intermediaries has been evidenced in some experimental murine models [9,14,15,17–21], scarce studies have focused on in situ tissue expression of these proteins [10,22], and none of them on a natural model.

Previous studies developed in scrapie-affected animals have led to conclusions about the glial role in the neurodegenerative progress that was extrapolated not only to other prion but also other neurodegenerative disorders [23–25]. More recently, this same *in vivo* model has been used to assess the changes of activation of glial cells associated with anti-inflammatory therapy [26]. This study constituted a powerful approach to the involvement of immune response in this neurodegenerative disease, confirming the occurrence of neuroinflammation in neurodegeneration. Specifically, a potential failure of astrocytes and a stimulation of phagocytosis of prion protein deposits by microglia were evidenced after dexamethasone (DEX) treatment. To examine the interglial communication mediated by cytokines in depth constitutes a main tool for advancement of the knowledge of how these mediators are really involved in neuroinflammatory mechanisms contributing to neurodegeneration [27–30]. It is indispensable to study the possible alteration of glial crosstalk that might enhance instead of prevent neuronal damage. Thus, it could be a crucial target for therapeutic approaches in prion diseases [31].

Overall, the actual role of prion protein-induced glial activation and subsequent cytokine expression during prion diseases is still incompletely understood. Consequently, to investigate the possible alterations of *in situ* cytokine expression in brain samples from animals naturally affected by scrapie and DEX treatment would be really helpful to determine whether these proteins could be significant factors in the progress of neurodegeneration in this group of diseases. Thus, the specific aim of this study is to assess the effect of the anti-inflammatory treatment on different cytokines which could be potentially related to neuroinflammation. Both immunohistochemical and expression patterns of different pro- and anti-inflammatory cytokines in several brain regions from treated and non-treated scrapie-affected sheep are compared in this study as a first step towards the ultimate goal that is to determine whether these proteins represent relevant targets in the immunopathogenesis of neurodegeneration.

2. Material and Methods

All the following experimental procedures were previously approved by the Ethical Committee of University of Zaragoza (Reference number: PI41/16, 03/10/2016). All efforts were made to minimize animal suffering during the experiments and to reduce the number of animals used.

All the analyses were performed on samples coming from animals included in a previously published study where, as cited above, the glial activation response in the progress of natural scrapie after chronic DEX treatment had been assessed [26]. All experimental details were provided in this previous manuscript, but briefly, a total of 25 sheep (age ranging from 4 to 10 years and all except for one of them with heterozygous alanine-arginine- glutamine and alanine-arginine-histidine, ARQ/ARH, presenting homozygous alanine-arginine- glutamine, ARQ/ARQ genotype) were included in this study: 10 healthy control (of which 4 treated and 6 non-treated) and 15 clinical scrapie Rasa Aragonesa ewes (10 treated plus 5 non-treated). Healthy controls were considered essential in order to specifically observe the effect of treatment (daily intramuscular, IM 0.04 mg/kg dose until euthanasia by endpoint criteria, 16 months the longest) in normal conditions in ovine species. After euthanasia with intravenous pentobarbital injection, necropsy of each sheep was performed and 80 samples were subsequently collected and distributed for different studies. One hemi-section from each sample was fixed by immersion in 4% paraformaldehyde for immunohistochemical studies and the other hemi-section was frozen at -80°C for molecular studies (RT-qPCR).

2.1. Immunohistochemical Techniques

Immunohistochemistry (IHC) was carried out in order to assess *in situ* neuroinflammatory profile associated with DEX treatment in all sheep. It was compared with non-treated sheep group in four encephalic areas (frontal cortex: Fc, cerebellum: Cb, obex: O and medulla oblongata: MO).

Prior 4 μm sectioning, paraffin-embedding of fixed samples was developed. After specific pre-treatments for antigen retrieval, specific immunohistochemical protocols by using specific primary antibodies against those cytokines or their receptors mainly studied in literature related (to our knowledge, IL-1 α , IL-1R, IL-2R, IL-6, IL-10R, TNFR and IFN γ R) were applied. EnVision system (DAKO, Glostrup, Denmark) and diaminobenzidine (DAB; DAKO, Glostrup, Denmark) were used as the visualization system and chromogen, respectively. Hematoxylin counterstaining and mounting in DPX was finally performed on all sections.

All slides were analysed by two independent observers scoring the intensity of immunostaining from 0 (absence) to 4 (maximum presence) by counting positive cells [32] in 5 microscopic fields in each brain region examined. Moreover, provided that cerebellum has been proposed as a pseudo reference region to detect neuroinflammation [33], close attention was paid to different profiles of cytokine distribution in this brain region. The focus was on Purkinje cells based on previous results referring this neuronal type as the most damaged while they are the most protected neurons in this area [23,26,34]. Table 1 summarizes all the primary antibodies and the protocols applied as following described.

Table 1. Antibodies used for immunohistochemical techniques and retrieval method applied for each one.

Antibody	Antigen	Type	Dilution	Retrieval Method	Source
IL-1 alpha	IL-1	Polyclonal	1:100	Autoclave 121 °C (citrate buffer 10%)	ThermoFisher
Anti-IL-1RN	IL-1R	Polyclonal	1:100	Autoclave 121 °C (citrate buffer 10%)	Sigma
IL-2R.1	IL-2R	Monoclonal	1:1000	PTLink 96 °C	ThermoFisher
8H12	IL-6	Monoclonal	1:40	Autoclave 121 °C (citrate buffer 10%)	ThermoFisher
OTI1D10	IL-10R	Monoclonal	1:250	PTLink 96 °C	ThermoFisher
Ber-H2	TNFR	Monoclonal	Ready to use	PTLink 96 °C	Dako
IFNGR1	IFN γ R	Polyclonal	1:200	Autoclave 121 °C (citrate buffer 10%)	ThermoFisher

2.1.1. IL-1, IL-1R, IL-6 and IFN γ R Detection

A pre-treatment consisting of hydrated heating at 121 °C in citrate buffer 10% for 20 min preceded the endogenous peroxidase blocking (DAKO, Glostrup, Denmark) for 5 min and incubation overnight 4 °C with different primary antibodies: polyclonal IL-1 α (1:100; ThermoFisher Scientific, Waltham, MA, USA), polyclonal IL-1RN (1:100, Sigma, St. Louis, MO, USA), monoclonal 8H12 (1:40; ThermoFisher Scientific, Waltham, MA, USA) or polyclonal IFNGR1 (1:200, ThermoFisher Scientific, Waltham, MA, USA).

2.1.2. IL-2R, IL-10R and TNFR Detection

A pre-treatment consisting of hydrated heating at 96 °C in citrate buffer 10% for 20 min preceded the endogenous peroxidase blocking (DAKO, Glostrup, Denmark) for 5 min and incubation with different primary monoclonal antibodies: IL-2R.1 (1:1000, overnight 4 °C; ThermoFisher Scientific, Waltham, MA, USA), OTI1D10 (1:250, overnight 4 °C; ThermoFisher Scientific, Waltham, MA, USA) or Ber-H2 (ready to use, 30 min RT; DAKO, Glostrup, Denmark).

2.2. RT-qPCR

Cerebellum and frontal cortex frozen tissues from treated and non-treated scrapie animals were included in the following comparative molecular analysis for some inflammatory markers.

2.2.1. RNA Purification

The purification of RNA was performed following the instructions of the supplier (RNeasy Lipid Tissue Mini kit, Qiagen, GmbH, Hilden, Germany). RNA integrity and 28S/18S ratios were determined with the Agilent Bioanalyzer (Agilent Technologies Inc, Santa Clara, CA, USA). Samples were treated with DNase digestion, and RNA concentration was evaluated using a NanoDrop Spectrophotometer (ThermoFisher Scientific, Waltham, MA, USA).

RNA samples with OD 260/280 ratios close to 5.0 were selected for reverse transcription. Finally, a total of 5 treated and 4 non-treated clinical sheep were included in this molecular analysis.

2.2.2. Retrotranscription

Retrotranscription of RNA into cDNA was performed according to the manufacturer's instructions (High-Capacity CDNA Reverse Transcription Kit, Applied Bio systems, Foster City, CA, USA).

2.2.3. RT-qPCR

Gene expression of IL-1, IL-6, IL-10Ra, IL-10Rb and IFN γ in both clinical non-treated and treated sheep was assessed. The parameters of the reactions were 50 °C for 2 min, 95 °C for 10 min, and 40 cycles of 95 °C for 15 sec and 60 °C for 1 min.

Data were assessed using the $\Delta\Delta$ Ct method, using Hypoxanthine Phosphoribosyl transferase 1 (HPRT-1) and β -glucuronidase (GUS- β) as reference genes. Table 2 shows TaqMan probes used for these molecular studies.

Table 2. Taqman probes used for RT-qPCR analysis.

Gene	Full Name	Reference	Source
Gus- β	β -glucuronidase (reference gene)	Oa04828868_m1	ThermoFisher
HPRT-1	Hypoxanthine Phosphoribosyltransferase 1 (reference gene)	Oa04825272_gH	ThermoFisher
IL-1 α	Interleukin 1 alpha	Oa04658681_m1	ThermoFisher
IL-6	Interleukin 6	Oa04656315_m1	ThermoFisher
IL-10Ra	Interleukin 10 receptor alpha	Oa04822455_m1	ThermoFisher
IL-10Rb	Interleukin 10 receptor beta	Oa04894070_m1	ThermoFisher
IFN γ	Interferon gamma	Oa04657364_m1	ThermoFisher

2.3. Statistical Analysis

For IHC results, the normality of distribution was first assessed by Kolmogorov-Smirnov test. The non-parametric Mann-Whitney *U* test was used to assess quantitative differences between non-treated and DEX treated groups.

Data of RT-qPCR were evaluated by Student's *t* test after assessing normality also by Kolmogorov-Smirnov test.

SPSS software (SPSS Statistics for Windows, Version 17.0, Chicago, IL, USA) was used for these analyses and significance in all cases was taken at * *p* < 0.05. All graphs were performed with GraphPad Prism 6.0 (San Diego, CA, USA). Data presented in figures are expressed as means and the standard error of the mean (mean \pm SEM).

3. Results

3.1. Immunohistochemistry

3.1.1. IL-1

DEX-treated controls always displayed higher intensity for IL-1 staining compared to the untreated samples. However, clinically treated animals showed lower differences compared to their respective untreated group and were even reversed (Figure 1A).




Figure 1. IL-1 immunostaining. (A) Note the evident higher intensity of immunostaining in medulla oblongata, MO from DEX treated control sheep compared to an untreated one. Scale bars: 100 μ m. (B) A significant effect of DEX was observed in MO from treated controls ($* p < 0.05$). However, in clinical stage, no significant changes were detected despite of the treatment.

The Mann–Whitney U test revealed significant effects of DEX in treated controls compared to untreated samples, showing an increase of IL-1 immunostaining in MO ($* p = 0.024$). Meanwhile, no changes were detected in clinically treated scrapie sheep depending on the treatment (Figure 1B).

In Cb, immunostaining for IL-1 was widespread in all layers (Figure 2A).

3.1.2. IL-1R

In general, immunostaining was lower in treated animals compared to non-treated ones, except for controls in Fc, where the patterns were exactly the opposite (higher). These differences evidently increased in O and Cb at clinical stage (Figure 3A).

Despite the fact that there were no statistically significant changes observed for this marker, a trend to a reduction in immunostaining in Cb from animals in the clinical stage was detected ($\# p = 0.082$) (Figure 3B).

IL-1R immunoreactivity in Cb was nearly exclusively located in cells surrounding Purkinje cells, suggesting morphology consistent with specific astrocytes (Figure 2B).

3.1.3. IL-2R

It is only relevant to point out that Fc showed an exacerbated increase of reactivity against this cytokine, regardless of treatment, and disease, in comparison with the other brain areas.

No statistically significant differences were found regarding treatment in both the control and clinical groups (Figure 4A).




Figure 2. Morphological findings in cerebellum immunostained with different primary antibodies. (A) Immunostaining for IL-1 was widespread in all layers. (B) IL-1R immunoreactivity was located mainly surrounding Purkinje cells, suggesting a morphology consistent with astrocytes. (C) IL-2R was mainly found in cytoplasm of Purkinje cells and cells appearing astrocytes. (D) IL-6 immunostaining was mainly present in Purkinje cells as intracytoplasmic staining, as well as stained cells resembling glial cells in both granular and molecular layers. (E) IL-10R immunostaining appeared spot intracytoplasmic in Purkinje cells as well as granular cells and other cellular type with astrocytic morphology. (F) Purkinje cells expressed TNFR in a very lower extent than the rest of markers. (G) IFN γ R immunostaining pattern was mainly localized in the cytoplasm and dendritic spines of Purkinje cells. Scale bars: 50 μ m.




Figure 3. *Cont.*




Figure 3. IL-1R immunostaining. (A) Differences observed after treatment in Cb at clinical stage are illustrated. Scale bars: 100 μ m. (B) While a subtle reduction of IL-1R in treated control group was observed in the rest of areas examined, in Fc it increased after DEX treatment. At clinical stage, a decrease of immunostaining in O and a trend ($\# p = 0.082$) to reduction in Cb were detected after treatment.




Figure 4. No significant differences were found either in control or in clinical groups for immunostaining intensity for (A) IL-2R (B) TNFR or (C) IFN γ R. A higher intensity in obex, O and medulla oblongata, MO after treatment was evidenced in controls that reversed in DEX clinical animals.

In Cb, IL-2R was limited to the cytoplasm of Purkinje cells and cells with an astrocytic appearance (Figure 2C).

3.1.4. IL-6

Immunostaining for IL-6 in DEX-treated controls was higher in all brain areas compared to untreated controls, except in O, where the labeling intensity was lower. This reduction in O was more evident at clinical stages of disease (Figure 5A).




Figure 5. IL-6 immunostaining. (A) Micrographs represent an increase of IL-6 immunoreactivity in frontal cortex, Fc in treated controls while slightly reduced in both treated groups in obex, O. Scale bars: 100 μ m. (B) DEX control group presented a significant increase in Fc (* $p < 0.05$) and a trend to a decrease in O (# $p = 0.071$). It was significantly decreased in this area when clinical group was treated (* $p < 0.05$).

The increase of immunostaining intensity reached significance in Fc of the control group when animals were DEX-treated ($* p = 0.040$). Meanwhile, the immunoreactivity for this cytokine showed a decreasing trend in control animals ($\# p = 0.071$) that converted into significant in O in the clinical group ($* p = 0.041$) (Figure 5B).

This neuromodulator peptide was mainly present in Purkinje cells as intracytoplasmic staining (Figure 2D). Moreover, the cytokine detected was present in specific cells resembling glial cells in both granular and molecular layers.

3.1.5. IL-10R

Immunostaining for this marker was the highest in all assessed samples in both the control and clinical groups, regardless of treatment, but especially in Fc, where the highest score was reached regardless of treatment or disease.

Along the same lines, although not significant, a trend toward a decrease ($\# p = 0.074$) in Cb of clinical sheep after treatment was observed (Figure 6A). In general, statistically, immunostaining for IL-10R did not reveal any changes between groups after treatment ($p > 0.05$). Nevertheless, a very relevant decrease in O intensity in treated clinical animals was evidenced to reach a lower intensity than untreated, while the staining intensity was higher in controls (Figure 6B).




Figure 6. IL-10R immunostaining. (A) Decrease in intensity in Cb of treated clinical sheep is illustrated. Scale bars: 100 μ m. (B) No significant changes were detected after treatment in control group, only a higher increase in O was outstanding. No significant changes were either observed in clinical stage after treatment, just a trend to lower intensity in Cb of treated clinical sheep ($\# p = 0.074$).

This marker stained Purkinje neurons consistent with a spot intracytoplasmic pattern. Additionally, the staining showed a high intensity in granular cells and some others with astrocytic morphology (Figure 2E).

3.1.6. TNFR

In general, immunostaining for TNFR was less intense in all brain areas compared to the rest of the cytokines assessed here.

The pattern of TNFR immunoreactivity was similar in the control and clinical animals, with no significance after treatment in any case ($p > 0.05$) (Figure 4B).

Morphologically, Purkinje cells in Cb expressed this receptor at a much lower extent than the rest of the cytokines assessed here (Figure 2F).

3.1.7. IFN γ R

Whereas in DEX-treated controls, the immunostaining was higher in O and MO, this difference was reversed in the DEX-treated clinical group. In contrast, immunostaining intensity increased in Cb from treated controls to exceed that of untreated animals when they were affected by clinical disease.

Nevertheless, no significant differences in intensity levels were found between treated and non-treated groups in any encephalic area for this marker ($p > 0.05$) (Figure 4C)

In Cb, its immunostaining pattern was mainly located in the cytoplasm and dendritic spines of Purkinje cells (Figure 2G).

3.2. RT-qPCR

Significantly, DEX treatment resulted in more than a three-fold increase in IFN γ mRNA levels in Fc of clinically treated sheep ($* p = 0.036$) (Figure 7A).




Figure 7. Results of gene expression by RT-qPCR in clinical sheep. (A) In Fc, an increase of IFN γ mRNA levels was observed ($* p = 0.036$). (B) In Cb, no significant changes were found in the mRNA expression of any cytokine analysed in this study, but all of them were slightly higher in clinical stage after DEX treatment.

Regarding Cb, no statistically significant changes were found in the mRNA expression of any cytokine analyzed here, although all of them were higher in clinically treated sheep (Figure 7B). Table 3 represents a summary recapitulative table of the results provided by application of the statistical analysis.

Table 3. Summary of significant (*) or trend (#) statistical results provided in this study.

Group	Marker Assessed (Methodology)	DEX Effect	Brain Area	Statistical Significance
Treated control	IL-1 α (IHC)	Increase	MO	* $p < 0.05$
Treated clinical	IL-1R (IHC)	Decrease	Cb	# $p = 0.082$
		Increase	Fc	* $p < 0.05$
Treated control	IL-6 (IHC)	Decrease	O	# $p = 0.071$
Treated clinical		Decrease	O	* $p < 0.05$
Treated clinical	IL-10R (IHC)	Decrease	Cb	# $p = 0.074$
Treated clinical	IFN γ (RT-qPCR)	Increase	Fc	* $p < 0.05$

4. Discussion

A great number of suggestions have led to hypotheses about the existence of a mixed inflammatory profile in prion diseases contributing to immune response [35–37]; on the one hand, some studies described a limited pro-inflammatory response, with no increases in IL-1 and TNF [18,22,38,39]; on the other hand, some others described increases of some factors, these same cytokines among them [9,10,15]. Actually, the presence of an impaired response of cytokines in mice orally infected with scrapie, imitating the natural route of entry, has been described [32]. However, these previous investigations in murine models have not been able to reach a consensus regarding the inflammatory profile in prion diseases because expression levels vary depending on the strain of mice and different combinations of scrapie inoculum [14,38], as well as different disease stages and detection techniques [37]. Moreover, direct detection of cytokines in the brain by IHC has been achieved only by some authors, probably because of the challenge associated with their detection as labile soluble proteins present at low concentrations [40]. A novel in situ cytokine profile is described here, slightly different from what has been previously described, possibly because the natural model was used here. It is crucial to highlight the relevance of results from natural models providing a fairer reflection of reality, since they are more reliable than those from experimental models mainly based on immunological discrepancies between sheep and rodent models even independently of prion diseases.

The findings presented in our previous study supported an impaired astroglial response at the clinical stage of scrapie, suggesting astroglial paralysis [26], as was recently described in late stages of Alzheimer's disease (AD) [41]. Our next goal consisted of providing specific information about the mechanisms underlying cytokine release from glial cells. For that purpose, the effects of long-term DEX treatment in sheep with natural scrapie and in healthy controls were examined here to determine whether this treatment would change the levels of neuroinflammatory markers in this neurodegenerative disease. To clarify the relationship between neurodegeneration and neuroinflammation is the ultimate goal.

As it has been reported that neuroinflammation in prion diseases is region-dependent [42], this study assessed four different brain areas. Moreover, no studies about in situ variations in cytokine levels after glucocorticoid (GC) treatment in prion diseases have been previously published, despite the fact that it is well known that chronic administration of GC inhibits both innate and adaptive immune systems, reducing a great variety of pro-inflammatory cytokines [43], such as IL-1, TNF [44], IL-6 and IFN γ [45,46]. In most cases, chronic exposition to GC suppresses mediators; however, on some occasions, GC can potentiate such immunity [47], especially in the central nervous system, which can exacerbate neuronal death [48]. Thus, in some cases of murine AD, neurodegeneration and exacerbation of pro-inflammatory mediators were observed after chronic exposition to this anti-inflammatory drug [49]. Consequently, the doses and duration of treatment are of huge importance for the immune system response. Additionally, acquired resistance with absence of response to treatment has also been described in rheumatoid arthritis [50].

Here, we show that the low dose of DEX chronically administered to healthy animals significantly increased the secretion of IL-1, specifically in one of the brain areas examined (MO). The early over-expression of IL-1 has been suggested as a candidate to contribute

to the development of murine [1,14,19] and ovine scrapie [3], as well as AD [51–54]. This increase has been also described in clinical and terminal stages in another scrapie murine model [22]. Furthermore, it is a well-known fact that expression of IL-1 induces oxide nitric synthase (iNOS) [55], and this production is involved in damage and neuronal death [56]. Enhanced neurodegeneration was observed when anti-inflammatory treatment was provided before the development of the neurodegenerative lesion itself in rats [57]. Taking into account this enhancement, DEX could be speculated to present a possible neurotoxic effect in control sheep. As our previous study about glial activation response after DEX treatment showed an increment in glial fibrillary acidic protein (GFAP) levels in treated controls, mainly observed also in MO [26], higher IL-1 levels could be related with to astrocytic activation, provided that some authors have closely related IL-1 to astrogliosis [1,14]. Conversely, no variations in the level of this mediator were evidenced after treatment when animals were scrapie-affected. This could reinforce the hypothesis that an astroglial dysfunction exists in scrapie progress [26]. An impairment of communication might be suggested between microglia and astroglia in clinical scrapie because IL-1 is not increased in this group of animals, although microglial population is shown to be activated [26].

In this natural model, the expression of IL-1R was slightly reduced in all treated cases (both control and clinical), except in Fc of controls. As that deficiency of IL-1R was demonstrated to prolong incubation time [58], delay disease onset and expand survival period of affected mice [19], this could point to the possibility of a neuroprotective role for DEX in both control and clinical sheep. The presence of neurotoxic reactive astrocytes induced by IL-1 and TNF released by microglia has been described [59]. Furthermore, a recent study showed that microglia have the power to auto renew themselves and that IL-1R signaling is implicated in this proliferative process [60]. Despite further studies to go in depth into this issue would be necessary to be performed, it could be speculated that DEX prevents the self-renewal of microglia, which might be related to the impairment of communication with astroglia observed in our previous study [26]. Additionally, IL-1R immunoreactivity was located mainly surrounding Purkinje cells in the cerebellum and appeared morphologically consistent with that of astrocytes, in agreement with previous studies in murine models [10,11,14,15]. Indeed, IL-1R has been described to be expressed by microglia, astrocytes and neurons in rodents [61,62], but particularly by cerebellar Purkinje neurons [62]. Importantly, it appears that IL-1R in neurons mediates the fast changes in neuronal excitability induced by IL-1, while IL-1R in astrocytes mediates effects of IL-1 on neuronal survival [63]. Therefore, although future experimental studies for separately analyzing expression of levels of IL-1R of astrocyte or microglia are required, evidence of the complexity of the IL-1 ligand/receptor, whose balance depends on the phase of the inflammatory response, is shown here [64]. Given that only few activated IL-1R molecules per cell are sufficient for activation of the target cell [65], this is of particular relevance for their signaling system. Overall, it is strongly evidenced here that both IL-1 and IL-1R play significant roles in the progress of natural ovine scrapie.

Regarding IL-2, it has been shown that this mediator can ameliorate amyloid pathology in mice with AD [66]. Nevertheless, neither this mediator nor its receptor have been analyzed in the prion diseases field before. Some trials revealed IL-2 anti-inflammatory effects [67]. However, in the present study, no differences were found regarding treatment in both the control and clinical groups, thus not attributing a relevant anti-inflammatory role of DEX regarding this cytokine. Fc has been shown to be the more reactive brain region against this mediator, and, similar to our study, it has been shown that immunoreactivity of IL-2 in the brains of both controls and AD patients was widespread [68]. Morphologically, in Cb, its receptor was generally found in the cytoplasm of Purkinje cells and astrocytes. Given that other authors have described that hippocampal neurons are rich in this receptor, which has been related to neuronal development [69,70], we could also suggest that IL-2 is involved in neuronal development of Purkinje cells in this encephalic area. Taken together,

although DEX treatment has had no apparent effect in modulating the levels of this peptide, a role of IL-2 in prion diseases should not be discarded before developing further studies.

Whereas DEX caused a significant increase in IL-6 staining intensity in Fc of the control group, which is in complete agreement with the strong astrogliosis observed in treated controls in our previous study [26], the immunoreactivity for this cytokine was reduced in O of both the treated control and the clinical group. Of particular interest is the fact that over-expression of IL-6 has been shown to produce neurologic disease in mouse, activating astrocytes and microglia [71]. Moreover, Burwinkel et al., 2004 [1] suggested that IL-6 might be implicated in the terminal stage of scrapie since it activates astrocytes in vivo [72]. Consequently, blocking of IL-6 has been proposed as a possible treatment against chronic inflammatory diseases [73]. Taking all this into account and given the evidence presented herein, DEX might act as neuroprotective for both control and clinical animals in one brain area (O), while it could be neurotoxic for controls in another area (Fc). Needless to say, IL-6 is a very peculiar cytokine that, depending on the context, exhibits two different behaviors: in acute inflammation models, it is anti-inflammatory [74,75], while it is pro-inflammatory in chronic inflammation models [76,77]. In summary, IL-6 can act as both pro- and anti-inflammatory, mediating both neurotrophic and neurotoxic effects on neurons [78]. Thus, although one study in mice postulated that IL-6 gene expression deficiency did not have any effect in prion pathogenesis [79], we strongly support the idea that this neuromodulator peptide is relevant to prion disease pathogenesis [3,9–15], as has been described for prion-like diseases [80–82].

Immunostaining of the marker specific for IL-10R was the highest compared to the rest of cytokines, which is in accordance with the treatment applied, as this mediator has been described as a potent anti-inflammatory cytokine [83] that interferes with nuclear factor κ B (NF- κ B) activation and blocks the synthesis of other pro-inflammatory cytokines [84], thus receiving considerable attention in neuroinflammation research [85]. Actually, Thackray et al., 2004 [20] demonstrated an accelerated pathogenesis of prion diseases in the absence of IL-10, with extension of survival time in mice [58], which is attributed to a protective role of IL-10 in prion diseases. Nevertheless, as no changes between groups after treatment have been detected (nor by IHC nor RT-qPCR), and even subtle decreases in intensity of this mediator in some brain areas in the clinical stage after treatment were observed in the present study, the immunomodulatory and anti-inflammatory roles of this cytokine in natural ovine scrapie cannot be completely confirmed, as have been recently described in models of AD [86,87].

Any changes were not detected for TNFR in any group, regardless of treatment. This supports studies that did not attribute a relevant role to this cytokine in scrapie progress [79] and prion pathogenesis [88]. However, TNF has been described to be implicated in panencephalic CJD pathogenesis [17], and an increment in incubation period in TNF *knockout* animals has also been reported [89]. Indeed, TNF is a very peculiar mediator, as both elevated [90] and reduced levels [91] of this peptide and its receptor have been described in AD. Consequently, either neuroprotective [92] or neurotoxic roles [93] have been suggested by other authors [94]. The discrepancies among studies regarding the role of this cytokine might be due to the different experimental models used. Thus, it is worth mentioning that, to our knowledge, this is the first study based on a natural model assessing in situ neuroinflammatory activity in prion diseases in relation to chronic anti-inflammatory therapy.

Regarding IFN γ R intensity levels, a similar behavior was demonstrated in all groups. However, immunostaining was slightly higher in some encephalic areas (O and MO) from controls after treatment, while this difference was diminished and even reversed in the clinically treated stage. Taking into account that microglia stimulate their division and adult neurogenesis by releasing IFN γ , among other mediators [95,96], this finding could be reflecting an attempt for microglial division in some brain regions in the controls. Meanwhile, no effect was proved at the clinical stage of the disease by IHC. Regarding molecular expression, strikingly, we found a significant increase in the quantity of IFN γ

mRNA by RT-qPCR in a specific area (Fc) of clinically treated sheep, and these results could be reflecting the microglial expansion observed in previous studies in natural scrapie [23,26]. However, no statistically significant changes were found in the mRNA expression levels of any cytokine in Cb, in agreement with the idea that neuroinflammation in prion diseases is region-dependent [42]. The discrepancies in results provided by molecular and IHC techniques are most likely due to the reduced number of samples available for RT-qPCR (9 samples in total, while 15 samples were used for IHC). In addition, as prolonged expression of IFN γ in central nervous system has been reported to lead to neuronal and glial cell damage [97], and activated astrocytes have been described to have high levels of IFN γ R in Parkinson's disease models, suggesting that this cytokine can mediate the toxic effects of neighboring neurons [98], DEX treatment could have had neurotoxic effects in both control and clinical animals. Further studies are necessary to clarify this discernible contradiction.

Concerning observations focused on cell damage in Purkinje cells as the most damaged but most protected neurons in the cerebellum [23,24,26,99], different immunostaining patterns of cytokines or receptors have been demonstrated in this study. Certainly, other authors found that immunostaining levels for cytokine receptors were higher in Purkinje cells than in other cells in mouse cerebellum [100]. Such distributions in mice are similar to those described in our study in sheep, confirming that cytokine receptors are present at high extent in Purkinje neurons in ovine cerebellum. This distribution could mean that the respective ligand of each receptor can act directly on Purkinje cells to alter their physiological properties, which possibly means that cytokines might be involved in this cellular damage around Purkinje cells, reconfirming the previously proposed role of Purkinje neurons in neuroinflammatory processes [101].

Overall, the therapeutic approach that has been tested here was demonstrated to directly influence the neuroinflammatory response. The results provided by this study confirm a limited modulating effect of low-dose DEX on the release of immunomodulator peptides from glial cells in a natural sheep scrapie model and reaffirm the paradoxical immunomodulator functions that glucocorticoids as DEX exhibit [102,103].

5. Conclusions

This is the first study using a glial-directed strategy in a natural ovine model of scrapie to investigate the contribution of inflammatory responses mediated by cytokines. An impaired communication between microglia and astroglia, which is mediated by cytokines, with IL-1 as one of the main actors, is suggested here. This study also emphasizes the complex interaction among several pleiotropic neuromodulator peptides and provides a global approach to clarify the neuroinflammatory process in natural prion diseases.

The cytokine profiles described in this study suggest the activation of some neurotoxicity-associated pathways. Consequently, targeting such pathways might be a new approach to modify the damaging effects of neuroinflammation. Further studies to determine which specific cellular types are expressing these cytokines and how these proteins are involved in cell signaling leading to neurodegeneration are essential.

Author Contributions: Conceptualization, research and supervision, M.M.; experimental methodology, I.M.G.; in vivo methodology, I.M.G., M.G., B.M., A.O. and T.B.; molecular methodology, M.C. and P.A.-B.; validation, I.F.; writing—original draft preparation, I.M.G. and M.M.; funding Acquisition, J.J.B. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by a grant from the Spanish *Ministerio de Educación, Cultura y Deporte* (FPU N° 15/03524) and from the Spain-France-Andorra Cooperation Program (POCTEFA), co-funded by the European Regional Development Fund (ERDF) (EFA 148/16 REDPRION).

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of University of Zaragoza (PI41/16, 03/10/2016).

Informed Consent Statement: Not applicable.

Acknowledgments: The authors are grateful to Sonia Gómez, Daniel Romanos and Sandra Felices for their excellent technical support. Authors would like to acknowledge the use of *Servicio de Apoyo Metodológico y Estadístico* (SAME)–IACS and *Servicio de Microscopía electrónica de sistemas biológicos* (University of Zaragoza).

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Burwinkel, M.; Riemer, C.; Schwarz, A.; Schultz, J.; Neidhold, S.; Bamme, T.; Baier, M. Role of Cytokines and Chemokines in Prion Infections of the Central Nervous System. *Int. J. Dev. Neurosci.* **2004**, *22*, 497–505. [[CrossRef](#)]
2. Pasquali, P.; Nonno, R.; Mandara, M.T.; Di Bari, M.A.; Ricci, G.; Petrucci, P.; Capuccini, S.; Cartoni, C.; Macri, A.; Agrimi, U. Intracerebral Administration of Interleukin-12 (IL-12) and IL-18 Modifies the Course of Mouse Scrapie. *BMC Vet. Res.* **2006**, *2*, 37. [[CrossRef](#)] [[PubMed](#)]
3. Marcos-Carcavilla, A.; Calvo, J.H.; Gonzalez, C.; Moazami-Goudarzi, K.; Laurent, P.; Bertaud, M.; Hayes, H.; Beattie, A.E.; Serrano, C.; Lyahyai, J.; et al. IL-1 Family Members as Candidate Genes Modulating Scrapie Susceptibility in Sheep: Localization, Partial Characterization, and Expression. *Mamm. Genome* **2007**, *18*, 53–63. [[CrossRef](#)] [[PubMed](#)]
4. Servida, F.; Ravasi, C.; Puricelli, M.; Formentin, E.A.; Dall'Ara, P.; Poli, G. Decrease in Neuroinflammation after Immunisation with Synthetic Prion Peptides in an Animal Model of Scrapie. *Vet. Res. Commun.* **2007**, *31* (Suppl. S1), 265–267. [[CrossRef](#)] [[PubMed](#)]
5. Schwartz, M.; Deczkowska, A. Neurological Disease as a Failure of Brain-Immune Crosstalk: The Multiple Faces of Neuroinflammation. *Trends Immunol.* **2016**, *37*, 668–679. [[CrossRef](#)] [[PubMed](#)]
6. Verkhatsky, A.; Rodriguez, J.J.; Parpura, V. Neurotransmitters and Integration in Neuronal-Astroglial Networks. *Neurochem. Res.* **2012**, *37*, 2326–2338. [[CrossRef](#)] [[PubMed](#)]
7. Burda, J.E.; Sofroniew, M.V. Reactive Gliosis and the Multicellular Response to CNS Damage and Disease. *Neuron* **2014**, *81*, 229–248. [[CrossRef](#)]
8. Pekny, M.; Pekna, M.; Messing, A.; Steinhauser, C.; Lee, J.M.; Parpura, V.; Hol, E.M.; Sofroniew, M.V.; Verkhatsky, A. Astrocytes: A Central Element in Neurological Diseases. *Acta Neuropathol.* **2016**, *131*, 323–345. [[CrossRef](#)] [[PubMed](#)]
9. Campbell, I.L.; Eddleston, M.; Kemper, P.; Oldstone, M.B.; Hobbs, M.V. Activation of Cerebral Cytokine Gene Expression and Its Correlation with Onset of Reactive Astrocyte and Acute-Phase Response Gene Expression in Scrapie. *J. Virol.* **1994**, *68*, 2383–2387. [[CrossRef](#)]
10. Williams, A.E.; van Dam, A.M.; Man, A.H.W.K.; Berkenbosch, F.; Eikelenboom, P.; Fraser, H. Cytokines, Prostaglandins and Lipocortin-1 Are Present in the Brains of Scrapie-Infected Mice. *Brain Res.* **1994**, *654*, 200–206. [[CrossRef](#)]
11. Williams, A.; Van Dam, A.M.; Ritchie, D.; Eikelenboom, P.; Fraser, H. Immunocytochemical Appearance of Cytokines, Prostaglandin E2 and Lipocortin-1 in the CNS during the Incubation Period of Murine Scrapie Correlates with Progressive PrP Accumulations. *Brain Res.* **1997**, *754*, 171–180. [[CrossRef](#)]
12. Peyrin, J.M.; Lasmez, C.I.; Haik, S.; Tagliavini, F.; Salmona, M.; Williams, A.; Ritchie, D.; Deslys, J.P.; Dormont, D. Microglial Cells Respond to Amyloidogenic PrP Peptide by the Production of Inflammatory Cytokines. *NeuroReport* **1999**, *10*, 723–729. [[CrossRef](#)] [[PubMed](#)]
13. Veerhuis, R.; Hoozemans, J.J.; Janssen, I.; Boshuizen, R.S.; Langeveld, J.P.; Eikelenboom, P. Adult Human Microglia Secrete Cytokines When Exposed to Neurotoxic Prion Protein Peptide: No Intermediary Role for Prostaglandin E2. *Brain Res.* **2002**, *925*, 195–203. [[CrossRef](#)]
14. Brown, A.R.; Webb, J.; Rebus, S.; Walker, R.; Williams, A.; Fazakerley, J.K. Inducible Cytokine Gene Expression in the Brain in the ME7/CV Mouse Model of Scrapie Is Highly Restricted, Is at a Strikingly Low Level Relative to the Degree of Gliosis and Occurs Only Late in Disease. *J. Gen. Virol.* **2003**, *84 Pt 9*, 2605–2611.
15. Kordek, R.; Nerurkar, V.R.; Liberski, P.P.; Isaacson, S.; Yanagihara, R.; Gajdusek, D.C. Heightened Expression of Tumor Necrosis Factor Alpha, Interleukin 1 Alpha, and Glial Fibrillary Acidic Protein in Experimental Creutzfeldt-Jakob Disease in Mice. *Proc. Natl. Acad. Sci. USA* **1996**, *93*, 9754–9758. [[CrossRef](#)]
16. Carroll, J.A.; Striebel, J.F.; Race, B.; Phillips, K.; Chesebro, B. Prion Infection of Mouse Brain Reveals Multiple New Upregulated Genes Involved in Neuroinflammation or Signal Transduction. *J. Virol.* **2015**, *89*, 2388–2404. [[CrossRef](#)]
17. Liberski, P.P.; Nerurkar, V.R.; Yanagihara, R.; Gajdusek, D.C. Tumor Necrosis Factor Alpha (TNF-Alpha) Is Involved in the Pathogenesis of the Panencephalopathic Type of Creutzfeldt-Jakob Disease. *Mol. Chem. Neuropathol.* **1995**, *24*, 223–225. [[CrossRef](#)]
18. Cunningham, C.; Boche, D.; Perry, V.H. Transforming Growth Factor Beta1, the Dominant Cytokine in Murine Prion Disease: Influence on Inflammatory Cytokine Synthesis and Alteration of Vascular Extracellular Matrix. *Neuropathol. Appl. Neurobiol.* **2002**, *28*, 107–119. [[CrossRef](#)]
19. Schultz, J.; Schwarz, A.; Neidhold, S.; Burwinkel, M.; Riemer, C.; Simon, D.; Kopf, M.; Otto, M.; Baier, M. Role of Interleukin-1 in Prion Disease-Associated Astrocyte Activation. *Am. J. Pathol.* **2004**, *165*, 671–820. [[CrossRef](#)]
20. Thackray, A.M.; McKenzie, A.N.; Klein, M.A.; Lauder, A.; Bujdosó, R. Accelerated Prion Disease in the Absence of Interleukin-10. *J. Virol.* **2004**, *78*, 13697–13707. [[CrossRef](#)]
21. Tribouillard-Tanvier, D.; Striebel, J.F.; Peterson, K.E.; Chesebro, B. Analysis of Protein Levels of 24 Cytokines in Scrapie Agent-Infected Brain and Glial Cell Cultures from Mice Differing in Prion Protein Expression Levels. *J. Virol.* **2009**, *83*, 11244–11253. [[CrossRef](#)] [[PubMed](#)]

22. Cunningham, C.; Wilcockson, D.C.; Campion, S.; Lunnon, K.; Perry, V.H. Central and Systemic Endotoxin Challenges Exacerbate the Local Inflammatory Response and Increase Neuronal Death during Chronic Neurodegeneration. *J. Neurosci.* **2005**, *25*, 9275–9284. [[PubMed](#)]
23. Hernandez, R.S.; Sarasa, R.; Toledano, A.; Badiola, J.J.; Monzon, M. Morphological Approach to Assess the Involvement of Astrocytes in Prion Propagation. *Cell Tissue Res.* **2014**, *358*, 57–63. [[CrossRef](#)] [[PubMed](#)]
24. Monzon, M.; Hernandez, R.S.; Garcés, M.; Sarasa, R.; Badiola, J.J. Glial Alterations in Human Prion Diseases: A Correlative Study of Astroglia, Reactive Microglia, Protein Deposition, and Neuropathological Lesions. *Medicine* **2018**, *97*, e0320. [[CrossRef](#)]
25. Garcés, M.; Guijarro, M.I.; Vargas, A.; Badiola, J.J.; Monzon, M. Neuroglial Patterns Are Shared by Cerebella from Prion and Prion-Like Disorder Affected Patients. *Mech. Ageing Dev.* **2019**, *184*, 111176. [[CrossRef](#)]
26. Guijarro, I.M.; Garcés, M.; Andres-Benito, P.; Marin, B.; Otero, A.; Barrio, T.; Carmona, M.; Ferrer, I.; Badiola, J.J.; Monzon, M. Assessment of Glial Activation Response in the Progress of Natural Scrapie after Chronic Dexamethasone Treatment. *Int. J. Mol. Sci.* **2020**, *21*, 3231. [[CrossRef](#)]
27. Morales, I.; Guzman-Martinez, L.; Cerda-Troncoso, C.; Farias, G.A.; Maccioni, R.B. Neuroinflammation in the Pathogenesis of Alzheimer's Disease. A Rational Framework for the Search of Novel Therapeutic Approaches. *Front. Cell. Neurosci.* **2014**, *8*, 112. [[CrossRef](#)]
28. DiSabato, D.J.; Quan, N.; Godbout, J.P. Neuroinflammation: The Devil Is in the Details. *J. Neurochem.* **2016**, *139* (Suppl. S2), 136–153. [[CrossRef](#)]
29. Ransohoff, R.M. How Neuroinflammation Contributes to Neurodegeneration. *Science* **2016**, *353*, 777–783. [[CrossRef](#)]
30. Kempuraj, D.; Thangavel, R.; Natteru, P.A.; Selvakumar, G.P.; Saeed, D.; Zahoor, H.; Zaheer, S.; Iyer, S.S.; Zaheer, A. Neuroinflammation Induces Neurodegeneration. *J. Neurol. Neurosurg. Spine* **2016**, *1*, 1003.
31. Garwood, C.J.; Pooler, A.M.; Atherton, J.; Hanger, D.P.; Noble, W. Astrocytes Are Important Mediators of Aβ-Induced Neurotoxicity and Tau Phosphorylation in Primary Culture. *Cell Death Dis.* **2011**, *2*, e167. [[CrossRef](#)] [[PubMed](#)]
32. Romero-Trejejo, J.L.; Gomez-Villamandos, J.C.; Pedrera, M.; Blanco, A.; Bautista, M.J.; Sanchez-Cordon, P.J. Immunohistochemical Study of Macrophage and Cytokine Dynamics in the Gut of Scrapie-Infected Mice. *Histol. Histopathol.* **2010**, *25*, 1025–1038. [[PubMed](#)]
33. Lyoo, C.H.; Ikawa, M.; Liow, J.S.; Zoghbi, S.S.; Morse, C.L.; Pike, V.W.; Fujita, M.; Innis, R.B.; Kreisl, W.C. Cerebellum Can Serve as a Pseudo-Reference Region in Alzheimer Disease to Detect Neuroinflammation Measured with PET Radioligand Binding to Translocator Protein. *J. Nucl. Med.* **2015**, *56*, 701–706. [[CrossRef](#)] [[PubMed](#)]
34. Sarasa, R.; Martinez, A.; Monleon, E.; Bolea, R.; Vargas, A.; Badiola, J.J.; Monzon, M. Involvement of Astrocytes in Transmissible Spongiform Encephalopathies: A Confocal Microscopy Study. *Cell Tissue Res.* **2012**, *350*, 127–134. [[CrossRef](#)] [[PubMed](#)]
35. Vincenti, J.E.; Murphy, L.; Grabert, K.; McColl, B.W.; Cancellotti, E.; Freeman, T.C.; Manson, J.C. Defining the Microglia Response during the Time Course of Chronic Neurodegeneration. *J. Virol.* **2015**, *90*, 3003–3017. [[CrossRef](#)] [[PubMed](#)]
36. Perry, V.H. Microglia. *Microbiol. Spectr.* **2016**, *4*. [[CrossRef](#)]
37. Obst, J.; Simon, E.; Mancuso, R.; Gomez-Nicola, D. The Role of Microglia in Prion Diseases: A Paradigm of Functional Diversity. *Front. Aging Neurosci.* **2017**, *9*, 207. [[CrossRef](#)]
38. Walsh, D.T.; Betmouni, S.; Perry, V.H. Absence of Detectable IL-1β Production in Murine Prion Disease: A Model of Chronic Neurodegeneration. *J. Neuropathol. Exp. Neurol.* **2001**, *60*, 173–182. [[CrossRef](#)]
39. Perry, V.H.; Cunningham, C.; Boche, D. Atypical Inflammation in the Central Nervous System in Prion Disease. *Curr. Opin. Neurol.* **2002**, *15*, 349–354. [[CrossRef](#)]
40. Boche, D.; Perry, V.H.; Nicoll, J.A. Review: Activation Patterns of Microglia and Their Identification in the Human Brain. *Neuropathol. Appl. Neurobiol.* **2013**, *39*, 3–18. [[CrossRef](#)]
41. Verkhatsky, A.; Rodrigues, J.J.; Pivoriunas, A.; Zorec, R.; Semyanov, A. Astroglial Atrophy in Alzheimer's Disease. *Pflug. Arch.* **2019**, *471*, 1247–1261. [[CrossRef](#)] [[PubMed](#)]
42. Llorens, F.; Lopez-Gonzalez, I.; Thune, K.; Carmona, M.; Zafar, S.; Andreoletti, O.; Zerr, I.; Ferrer, I. Subtype and Regional-Specific Neuroinflammation in Sporadic Creutzfeldt-Jakob Disease. *Front. Aging Neurosci.* **2014**, *6*, 198. [[CrossRef](#)] [[PubMed](#)]
43. Forster, C.; Waschke, J.; Burek, M.; Leers, J.; Drenckhahn, D. Glucocorticoid Effects on Mouse Microvascular Endothelial Barrier Permeability Are Brain Specific. *J. Physiol.* **2006**, *573 Pt 2*, 413–425. [[CrossRef](#)]
44. De Bosscher, K.; Vanden Berghe, W.; Haegeman, G. The Interplay between the Glucocorticoid Receptor and Nuclear Factor-κB or Activator Protein-1: Molecular Mechanisms for Gene Repression. *Endocr. Rev.* **2003**, *24*, 488–522. [[CrossRef](#)] [[PubMed](#)]
45. Munck, A.; Guyre, P.M.; Holbrook, N.J. Physiological Functions of Glucocorticoids in Stress and Their Relation to Pharmacological Actions. *Endocr. Rev.* **1984**, *5*, 25–44. [[CrossRef](#)] [[PubMed](#)]
46. Guerne, P.A.; Carson, D.A.; Lotz, M. IL-6 production by Human Articular Chondrocytes. Modulation of Its Synthesis by Cytokines, Growth Factors, and Hormones In Vitro. *J. Immunol.* **1990**, *144*, 499–505. [[PubMed](#)]
47. Bowers, S.L.; Bilbo, S.D.; Dhabhar, F.S.; Nelson, R.J. Stressor-Specific Alterations in Corticosterone and Immune Responses in Mice. *Brain Behav. Immun.* **2008**, *22*, 105–113. [[CrossRef](#)] [[PubMed](#)]
48. Sorrells, S.F.; Caso, J.R.; Munhoz, C.D.; Sapolsky, R.M. The Stressed CNS: When Glucocorticoids Aggravate Inflammation. *Neuron* **2009**, *64*, 33–39. [[CrossRef](#)]

49. Hu, W.; Zhang, Y.; Wu, W.; Yin, Y.; Huang, D.; Wang, Y.; Li, W.; Li, W. Chronic Glucocorticoids Exposure Enhances Neurodegeneration in the Frontal Cortex and Hippocampus via NLRP-1 Inflammasome Activation in Male Mice. *Brain Behav. Immun.* **2016**, *52*, 58–70. [[CrossRef](#)]
50. Kirwan, J.R. Glucocorticoid Resistance in Patients with Rheumatoid Arthritis. *Scand. J. Rheumatol.* **2007**, *36*, 165–166. [[CrossRef](#)]
51. Mrak, R.E.; Sheng, J.G.; Griffin, W.S. Glial Cytokines in Alzheimer's Disease: Review and Pathogenic Implications. *Hum. Pathol.* **1995**, *26*, 816–823. [[CrossRef](#)]
52. Akiyama, H.; Barger, S.; Barnum, S.; Bradt, B.; Bauer, J.; Cole, G.M.; Cooper, N.R.; Eikelenboom, P.; Emmerling, M.; Fiebich, B.L.; et al. Inflammation and Alzheimer's Disease. *Neurobiol. Aging* **2000**, *21*, 383–421. [[CrossRef](#)]
53. Griffin, W.S.; Mrak, R.E. Interleukin-1 in the Genesis and Progression of and Risk for Development of Neuronal Degeneration in Alzheimer's Disease. *J. Leukoc. Biol.* **2002**, *72*, 233–238. [[PubMed](#)]
54. Sastre, M.; Klockgether, T.; Heneka, M.T. Contribution of Inflammatory Processes to Alzheimer's Disease: Molecular Mechanisms. *Int. J. Dev. Neurosci.* **2006**, *24*, 167–176. [[CrossRef](#)] [[PubMed](#)]
55. Serou, M.J.; DeCoster, M.A.; Bazan, N.G. Interleukin-1 Beta Activates Expression of Cyclooxygenase-2 and Inducible Nitric oxide Synthase in Primary Hippocampal Neuronal Culture: Platelet-Activating Factor as a Preferential Mediator of Cyclooxygenase-2 Expression. *J. Neurosci. Res.* **1999**, *58*, 593–598. [[CrossRef](#)]
56. Zheng, Y.; Horii, A.; Appleton, I.; Darlington, C.L.; Smith, P.F. Damage to the Vestibular Inner Ear Causes Long-Term Changes in Neuronal Nitric Oxide Synthase Expression in the Rat Hippocampus. *Neuroscience* **2001**, *105*, 1–5. [[CrossRef](#)]
57. Dinkel, K.; MacPherson, A.; Sapolsky, R.M. Novel Glucocorticoid Effects on Acute Inflammation in the CNS. *J. Neurochem.* **2003**, *84*, 705–716. [[CrossRef](#)]
58. Tamguney, G.; Giles, K.; Glidden, D.V.; Lessard, P.; Wille, H.; Tremblay, P.; Groth, D.F.; Yehiely, F.; Korth, C.; Moore, R.C.; et al. Genes Contributing to Prion Pathogenesis. *J. Gen. Virol.* **2008**, *89 Pt 7*, 1777–1788. [[CrossRef](#)]
59. Liddel, S.A.; Guttenplan, K.A.; Clarke, L.E.; Bennett, F.C.; Bohlen, C.J.; Schirmer, L.; Bennett, M.L.; Munch, A.E.; Chung, W.S.; Peterson, T.C.; et al. Neurotoxic Reactive Astrocytes Are Induced by Activated Microglia. *Nature* **2017**, *541*, 481–487. [[CrossRef](#)]
60. Bruttger, J.; Karram, K.; Wortge, S.; Regen, T.; Marini, F.; Hoppmann, N.; Klein, M.; Blank, T.; Yona, S.; Wolf, Y.; et al. Genetic Cell Ablation Reveals Clusters of Local Self-Renewing Microglia in the Mammalian Central Nervous System. *Immunity* **2015**, *43*, 92–106. [[CrossRef](#)]
61. Ban, E.; Milon, G.; Prudhomme, N.; Fillion, G.; Haour, F. Receptors for Interleukin-1 (Alpha and Beta) in Mouse Brain: Mapping and Neuronal Localization in Hippocampus. *Neuroscience* **1991**, *43*, 21–30. [[PubMed](#)]
62. French, R.A.; VanHoy, R.W.; Chizzonite, R.; Zachary, J.F.; Dantzer, R.; Parnet, P.; Bluthé, R.M.; Kelley, K.W. Expression and Localization of p80 and p68 Interleukin-1 Receptor Proteins in the Brain of Adult Mice. *J. Neuroimmunol.* **1999**, *93*, 194–202. [[CrossRef](#)]
63. Ravizza, T.; Vezzani, A. Status Epilepticus Induces Time-Dependent Neuronal and Astrocytic Expression of Interleukin-1 Receptor Type I in the Rat Limbic System. *Neuroscience* **2006**, *137*, 301–308. [[CrossRef](#)] [[PubMed](#)]
64. Spulber, S.; Bartfai, T.; Schultzberg, M. IL-1/IL-1ra Balance in the Brain Revisited—Evidence from Transgenic Mouse Models. *Brain Behav. Immun.* **2009**, *23*, 573–579. [[CrossRef](#)] [[PubMed](#)]
65. Dinarello, C.A. Biologic Basis for Interleukin-1 in Disease. *Blood* **1996**, *87*, 2095–2147. [[CrossRef](#)]
66. Alves, S.; Churlaud, G.; Audrain, M.; Michaelsen-Preusse, K.; Fol, R.; Souchet, B.; Braudeau, J.; Korte, M.; Klatzmann, D.; Cartier, N. Interleukin-2 Improves Amyloid Pathology, Synaptic Failure and Memory in Alzheimer's Disease Mice. *Brain* **2017**, *140*, 826–842. [[CrossRef](#)]
67. Saadoun, D.; Terrier, B.; Cacoub, P. Interleukin-25: Key Regulator of Inflammatory and Autoimmune Diseases. *Curr. Pharm. Des.* **2011**, *17*, 3781–3785. [[CrossRef](#)]
68. Lubner-Narod, J.; Rogers, J. Immune System Associated Antigens Expressed by Cells of the Human Central Nervous System. *Neurosci. Lett.* **1988**, *94*, 17–22. [[CrossRef](#)]
69. Sarder, M.; Abe, K.; Saito, H.; Nishiyama, N. Comparative Effect of IL-2 and IL-6 on Morphology of Cultured Hippocampal Neurons from Fetal Rat Brain. *Brain Res.* **1996**, *715*, 9–16. [[CrossRef](#)]
70. Dansokho, C.; Ahmed, D.A.; Aid, S.; Toly-Ndour, C.; Chaigneau, T.; Calle, V.; Cagnard, N.; Holzenberger, M.; Piaggio, E.; Aucouturier, P.; et al. Regulatory T Cells Delay Disease Progression in Alzheimer-Like Pathology. *Brain* **2016**, *139 Pt 4*, 1237–1251. [[CrossRef](#)]
71. Campbell, I.L.; Abraham, C.R.; Masliah, E.; Kemper, P.; Inglis, J.D.; Oldstone, M.B.; Mucke, L. Neurologic Disease Induced in Transgenic Mice by Cerebral Overexpression of Interleukin 6. *Proc. Natl. Acad. Sci. USA* **1993**, *90*, 10061–10065. [[CrossRef](#)] [[PubMed](#)]
72. Hafiz, F.B.; Brown, D.R. A Model for the Mechanism of Astroglialosis in Prion Disease. *Mol. Cell. Neurosci.* **2000**, *16*, 221–232. [[CrossRef](#)] [[PubMed](#)]
73. Gabay, C. Interleukin-6 and Chronic Inflammation. *Arthritis Res. Ther.* **2006**, *8* (Suppl. S2), S3. [[CrossRef](#)] [[PubMed](#)]
74. Xing, Z.; Gaudie, J.; Cox, G.; Baumann, H.; Jordana, M.; Lei, X.F.; Achong, M.K. IL-6 Is an Antiinflammatory Cytokine Required for Controlling Local or Systemic Acute Inflammatory Responses. *J. Clin. Investig.* **1998**, *101*, 311–320. [[CrossRef](#)]
75. Yasukawa, H.; Ohishi, M.; Mori, H.; Murakami, M.; Chinen, T.; Aki, D.; Hanada, T.; Takeda, K.; Akira, S.; Hoshijima, M.; et al. IL-6 Induces an Anti-Inflammatory Response in the Absence of SOCS3 in Macrophages. *Nat. Immunol.* **2003**, *4*, 551–556. [[CrossRef](#)]
76. Tilg, H.; Dinarello, C.A.; Mier, J.W. IL-6 and APPs: Anti-Inflammatory and Immunosuppressive Mediators. *Immunol. Today* **1997**, *18*, 428–432. [[CrossRef](#)]

77. Yamamoto, M.; Yoshizaki, K.; Kishimoto, T.; Ito, H. IL-6 Is Required for the Development of Th1 Cell-Mediated Murine Colitis. *J. Immunol.* **2000**, *164*, 4878–4882. [[CrossRef](#)]
78. Allan, S.M.; Rothwell, N.J. Cytokines and Acute Neurodegeneration. *Nat. Rev. Neurosci.* **2001**, *2*, 734–744. [[CrossRef](#)]
79. Mabbott, N.A.; Williams, A.; Farquhar, C.F.; Pasparakis, M.; Kollias, G.; Bruce, M.E. Tumor Necrosis Factor Alpha-Deficient, But not Interleukin-6-deficient, Mice Resist Peripheral Infection with Scrapie. *J. Virol.* **2000**, *74*, 3338–3344. [[CrossRef](#)]
80. Bauer, J.; Strauss, S.; Volk, B.; Berger, M. IL-6-mediated Events in Alzheimer's Disease Pathology. *Immunol. Today* **1991**, *12*, 422. [[CrossRef](#)]
81. Strauss, S.; Bauer, J.; Ganter, U.; Jonas, U.; Berger, M.; Volk, B. Detection of Interleukin-6 and Alpha 2-macroglobulin Immunoreactivity in Cortex and Hippocampus of Alzheimer's Disease Patients. *Lab. Investig.* **1992**, *66*, 223–230. [[PubMed](#)]
82. Wood, J.A.; Wood, P.L.; Ryan, R.; Graff-Radford, N.R.; Pilapil, C.; Robitaille, Y.; Quirion, R. Cytokine Indices in Alzheimer's Temporal Cortex: No Changes in Mature IL-1 Beta or IL-1RA but Increases in the Associated Acute Phase Proteins IL-6, Alpha 2-macroglobulin and C-reactive Protein. *Brain Res.* **1993**, *629*, 245–252. [[CrossRef](#)]
83. Couper, K.N.; Blount, D.G.; Riley, E.M. IL-10: The Master Regulator of Immunity to Infection. *J. Immunol.* **2008**, *180*, 5771–5777. [[CrossRef](#)] [[PubMed](#)]
84. Wang, P.; Wu, P.; Siegel, M.I.; Egan, R.W.; Billah, M.M. Interleukin (IL)-10 Inhibits Nuclear Factor Kappa B (NF Kappa B) Activation in Human Monocytes. IL-10 and IL-4 Suppress Cytokine Synthesis by Different Mechanisms. *J. Biol. Chem.* **1995**, *270*, 9558–9563. [[CrossRef](#)]
85. Lobo-Silva, D.; Carriche, G.M.; Castro, A.G.; Roque, S.; Saraiva, M. Balancing the Immune Response in the Brain: IL-10 and Its Regulation. *J. Neuroinflamm.* **2016**, *13*, 297. [[CrossRef](#)]
86. Chakrabarty, P.; Li, A.; Ceballos-Diaz, C.; Eddy, J.A.; Funk, C.C.; Moore, B.; DiNunno, N.; Rosario, A.M.; Cruz, P.E.; Verbeeck, C.; et al. IL-10 Alters Immunoproteostasis in APP Mice, Increasing Plaque Burden and Worsening Cognitive Behavior. *Neuron* **2015**, *85*, 519–533. [[CrossRef](#)]
87. Guillot-Sestier, M.V.; Doty, K.R.; Gate, D.; Rodriguez, J., Jr.; Leung, B.P.; Rezai-Zadeh, K.; Town, T. Il10 Deficiency Rebalances Innate Immunity to Mitigate Alzheimer-Like Pathology. *Neuron* **2015**, *85*, 534–548. [[CrossRef](#)]
88. Prinz, M.; Montrasio, F.; Klein, M.A.; Schwarz, P.; Priller, J.; Odermatt, B.; Pfeffer, K.; Aguzzi, A. Lymph Nodal Prion Replication and Neuroinvasion in Mice Devoid of Follicular Dendritic Cells. *Proc. Natl. Acad. Sci. USA* **2002**, *99*, 919–924. [[CrossRef](#)]
89. Mabbott, N.A.; McGovern, G.; Jeffrey, M.; Bruce, M.E. Temporary Blockade of the Tumor Necrosis Factor Receptor Signaling Pathway Impedes the Spread of Scrapie to the Brain. *J. Virol.* **2002**, *76*, 5131–5139. [[CrossRef](#)]
90. Zhao, M.; Cribbs, D.H.; Anderson, A.J.; Cummings, B.J.; Su, J.H.; Wasserman, A.J.; Cotman, C.W. The Induction of the TNFalpha Death Domain Signaling Pathway in Alzheimer's Disease Brain. *Neurochem. Res.* **2003**, *28*, 307–318. [[CrossRef](#)]
91. Cacabelos, R.; Alvarez, X.A.; Franco-Maside, A.; Fernandez-Novoa, L.; Caamano, J. Serum Tumor Necrosis Factor (TNF) in Alzheimer's Disease and Multi-Infarct Dementia. *Methods Find. Exp. Clin. Pharmacol.* **1994**, *16*, 29–35. [[PubMed](#)]
92. Sakudo, A.; Lee, D.C.; Saeki, K.; Matsumoto, Y.; Itohara, S.; Onodera, T. Tumor Necrosis Factor Attenuates Prion Protein-Deficient Neuronal Cell Death by Increases in Anti-Apoptotic Bcl-2 Family Proteins. *Biochem. Biophys. Res. Commun.* **2003**, *310*, 725–729. [[CrossRef](#)] [[PubMed](#)]
93. Goetz, F.W.; Planas, J.V.; MacKenzie, S. Tumor Necrosis Factors. *Dev. Comp. Immunol.* **2004**, *28*, 487–497. [[CrossRef](#)]
94. Scherbel, U.; Raghupathi, R.; Nakamura, M.; Saatman, K.E.; Trojanowski, J.Q.; Neugebauer, E.; Marino, M.W.; McIntosh, T.K. Differential Acute and Chronic Responses of Tumor Necrosis Factor-Deficient Mice to Experimental Brain Injury. *Proc. Natl. Acad. Sci. USA* **1999**, *96*, 8721–8726. [[CrossRef](#)] [[PubMed](#)]
95. Kim, S.U.; de Vellis, J. Microglia in Health and Disease. *J. Neurosci. Res.* **2005**, *81*, 302–313. [[CrossRef](#)]
96. Sato, K. Effects of Microglia on Neurogenesis. *Glia* **2015**, *63*, 1394–1405. [[CrossRef](#)] [[PubMed](#)]
97. Corbin, J.G.; Kelly, D.; Rath, E.M.; Baerwald, K.D.; Suzuki, K.; Popko, B. Targeted CNS Expression of Interferon-Gamma in Transgenic Mice Leads to Hypomyelination, Reactive Gliosis, and Abnormal Cerebellar Development. *Mol. Cell. Neurosci.* **1996**, *7*, 354–370. [[CrossRef](#)]
98. Hashioka, S.; Klegeris, A.; Schwab, C.; McGeer, P.L. Interferon-Gamma-Dependent Cytotoxic Activation of Human Astrocytes and Astrocytoma Cells. *Neurobiol. Aging* **2009**, *30*, 1924–1935. [[CrossRef](#)]
99. Sarna, J.R.; Hawkes, R. Patterned Purkinje Cell Death in the Cerebellum. *Prog. Neurobiol.* **2003**, *70*, 473–507. [[CrossRef](#)]
100. Nelson, T.E.; Campbell, I.L.; Gruol, D.L. Altered Physiology of Purkinje Neurons in Cerebellar Slices from Transgenic Mice with Chronic Central Nervous System Expression of Interleukin-6. *Neuroscience* **1999**, *89*, 127–136.
101. Ragagnin, A.; Ezpeleta, J.; Guillemain, A.; Boudet-Devaud, F.; Haerberle, A.M.; Demais, V.; Vidal, C.; Demuth, S.; Beringue, V.; Kellermann, O.; et al. Cerebellar Compartmentation of Prion Pathogenesis. *Brain Pathol.* **2017**, *28*, 240–263. [[CrossRef](#)] [[PubMed](#)]
102. Munck, A.; Naray-Fejes-Toth, A. The Ups and Downs of Glucocorticoid Physiology. Permissive and Suppressive Effects Revisited. *Mol. Cell. Endocrinol.* **1992**, *90*, C1–C4. [[CrossRef](#)]
103. Filaretova, L.; Podvigina, T.; Bagaeva, T.; Morozova, O. Dual Action of Glucocorticoid Hormones on the Gastric Mucosa: How the Gastroprotective Action Can Be Transformed to the Ulcerogenic One. *Inflammopharmacology* **2009**, *17*, 15–22. [[CrossRef](#)] [[PubMed](#)]